Board of Directors

Doug Lawrence

Doug Lawrence is a 27-year veteran of the medical devices industry, with a diverse background in R&D, marketing, finance and general management roles. Mr. Lawrence has significant experience raising capital as well as financial management, operational experience, and extensive commercial expertise. As Chief Executive Officer, Mr. Lawrence is directly responsible for leading the company’s strategic initiatives, financing and capital management, and all commercial healthcare activities including the execution of the company’s go-to-market strategy as well as establishing distribution and sales channels that drive and expand commercial value.

Prior to joining RPS Diagnostics, Mr. Lawrence was the Chief Executive Officer at CeQur, a startup insulin patch pump company in Marlboro, MA, from 2014 to 2016. Prior to CEQUR, Mr. Lawrence was an executive at Becton Dickinson & Company, where he led the corporate point-of-care diagnostics initiative, and served as global Vice President for the company’s Insulin Injection business, where he led global launches of a number of insulin delivery innovations. Mr. Lawrence’s background includes medical device and pharmaceutical industry experience at category-leading companies including Procter & Gamble and Ohmeda/The BOC Group. Prior to his work at BD Diabetes Care, he was responsible for the development and launch of innovative products in ophthalmology, infusion therapy, critical care, and consumer health.

Mr. Lawrence has a degree in Systems Engineering from the University of Pennsylvania as well as business degrees from the University of Pennsylvania’s Wharton School and Northwestern University’s Kellogg School. He is Chairman Emeritus of the Massachusetts Medical Device Industry Council and Board Member at H2L Medical.

Robert Sambursky, MD

Robert Sambursky, MD is one of the original founders of RPS Diagnostics, and has served various roles including Chief Executive Officer from July 2012 until June 2017, President since 2010, and Chief Medical Officer since 2008. He is an inaugural member of both the Leadership Team and Board of Directors. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology, and infectious disease. He conceived numerous patents, developed a point-of-care (POC) diagnostic platform, designed clinical protocols, and served as the regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as both U.S. FDA 510(k) clearance and CLIA waiver designations. Further, Dr. Sambursky was responsible for all medical affairs activities including development of key opinion leaders (KOLs), clinical marketing and product training, and creating a successful reimbursement strategy that lead to the issuance of dedicated U.S. Medicare CPT codes.

Currently Dr. Sambursky continues to serve as President as well as Chief Technology and Medical Officer where his leadership responsibilities include strategic planning and business development, oversight of innovation, research and new product development, and leading clinical and regulatory affairs, KOL development, health policy and government affairs, reimbursement, and evidence based marketing. He is considered a subject area expert and serves as a global spokesperson.

In addition, Dr. Sambursky is a practicing, board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He currently sits on several ophthalmic pharmaceutical advisory boards, serves as an editorial consultant to several professional organizations and publications, is a member of the Vanguard Ophthalmology Society, and has co-authored numerous articles in medical journals. He currently serves as a consultant for Quidel Corp. Dr. Sambursky earned his BA in Biology from Brown University, MA in Medical Sciences with a concentration in biochemistry and microbiology from Boston University, and MD from Boston University School of Medicine. He completed his medical internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.

Craig Mallitz

Craig Malltiz is a co-founder, President, and member of the Board of Directors of the Mallitz Investment Group (MIG). Mr. Mallitz spent more than seven years with SAC Capital and CR Intrinsic as a Portfolio Manager and Senior Analyst. While at SAC/CR Intrinsic, he managed a portfolio focused on Technology, Media, and Telecom (TMT) and was a senior analyst for five years on a portfolio focused on TMT. Including his years as an analyst, his or his team’s returns were positive six of the seven years. Mr. Mallitz was ranked in top tier of all SAC analysts for five years and was named by Institutional Investor Top Hedge Fund Analyst – Telecommunications in 2008. Prior to SAC/CR Intrinsic, he was a Vice President, Senior Analyst for wireless services for Legg Mason from 2000-2004.

Tammer Fahmy

Tammer Fahmy is a Managing Director and member of the investment committee of the Mallitz Investment Group (MIG). He is responsible for origination, underwriting, and structuring of debt and equity investments, as well as oversight of the firm’s existing investments. Mr. Fahmy began his career as an M&A analyst with Morgan Stanley, followed by analyst positions at Sirius Radio and Mark Asset Management. In 2004 he joined Saddle Point Partners with primary responsibilities of independent new idea generation, investment analysis, valuation, structuring, due diligence, and investment monitoring. In 2009, Mr. Fahmy took a position with Metrica Investments, LLC/Cicerone Capital LLC where was responsible for deal origination, execution, structuring, deal marketing, and investor coverage. He transitioned from VP at Cicerone to Partner with Metrica Investments with team continuity. Mr. Fahmy graduated Magna Cum Laude in 1998, and earned a Bachelor of Business Administration with emphasis in Finance from the University of Michigan Ross School of Business Administration.